In the U.S., dermaPACE® has recently completed a 206-patient, randomized, double-blinded, sham-controlled, pivotal Phase III, Investigational Device Exemption (IDE) study for the treatment of diabetic foot ulcers. The results were highly positive and clinically relevant.
Request Product Information